If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
207
results.
Updated on
14/10/2025 [06:50:00]
Absstract of: CN120754061A
本发明涉及肿瘤免疫治疗技术领域。本发明提供了一种响应型抗原捕获纳米平台及其制备方法和应用。本发明的产品通过静脉注射等全身给药方式应用；能特异性响应肿瘤微环境中的过氧亚硝酸盐，实现肿瘤部位的精准激活；可通过高效共价捕获肿瘤相关抗原，将抗原递送至抗原呈递细胞中，以此增强抗肿瘤免疫应答；结合光动力治疗能显著抑制肿瘤生长。
Absstract of: CN120754062A
本申请属于抗肿瘤药物制备技术领域，更具体地，涉及一种靶向阻断交感神经与肿瘤串扰的载药杂化纳米囊泡及其制备方法。本申请提供的载药杂化纳米囊泡，包括M1型巨噬细胞来源纳米囊泡与酸敏感脂质体水合形成的杂化纳米囊泡，以及该杂化纳米囊泡包裹的能够抑制交感神经与肿瘤串扰的药物。该载药杂化纳米囊泡能够有效靶向肿瘤组织，降解肿瘤胞外致密基质，并能够响应肿瘤微酸环境释放药物，实现药物在肿瘤部位的高效富集以及深度渗透，有效阻断慢性应激条件下交感神经与肿瘤之间的互作，抑制肿瘤中的神经浸润与神经递质分泌，改善肿瘤免疫微环境，从而有效抑制肿瘤生长。此外，上述载药杂化纳米囊泡的生物安全性高，具备良好的临床应用前景。
Absstract of: US2025312491A1
Provided herein are compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed by the aggregation of misfolded transthyretin (TTR) proteins. Such conditions include, but are not limited to, polyneuropathy due to hereditary transthyretin amyloidosis (hATTR-PN) and hereditary cardiomyopathy due to transthyretin amyloidosis (hATTR-CM), both associated with autosomal dominant mutations of the TTR gene, and an age-related cardiomyopathy associated with wild-type TTR proteins (ATTRwt), also known as senile cardiac amyloidosis.
Absstract of: CN120757505A
本发明涉及一种二烃基咪唑仿生型脂质化合物及其制备方法和应用，二烃基咪唑仿生型脂质化合物结构仿天然磷脂设计，在咪唑的4位与5位上修饰不少于10个碳原子的烃基，且在2位上修饰不同烷基链长的伯胺；二烃基咪唑仿生型脂质化合物与治疗性药物以及其他辅料混合，能够制备得到治疗性药物被装载在内的脂质纳米颗粒，能够作为药物递送系统用于脑靶向药物的制备。二烃基咪唑仿生型脂质具备动态调控血脑屏障的功能，可以实现血脑屏障的可逆开放；形成的载药脂质组合物能够穿越血脑屏障并较好的实现所装载治疗性药物的脑靶向递送；由二烃基咪唑仿生型脂质组成的载药脂质组合物属于新一代仿生纳米药物载体，为实现不同种类药物的脑靶向递送提供了新策略。
Absstract of: CN120754155A
本发明公开解吉那保石油醚提取物在治疗肝癌中的应用，属于肝癌防治领域；本发明提出了解吉那保石油醚提取物(GC‑PE)在治疗或者预防肝癌中的应用，揭示了GC‑PE治疗可显著降低人肝癌细胞Hep‑G2的细胞活力，其作用机制可能与促进Hep‑G2细胞周期阻滞、凋亡有关。将GC‑PE与阳性药紫杉醇(PTX)进行比较，其抑制肝癌细胞增殖和侵袭的效果更加显著。网络药理学分析结果显示，解吉那保可能通过PI3K/AKT信号通路促进肝癌细胞周期阻滞、细胞凋亡，并通过分子对接预测解吉那保中的活性成分与PI3K/AKT信号通路中的关键靶蛋白PIK3CA结合，发挥其抗肿瘤的作用。
Absstract of: CN120754262A
本发明公开了一种核酸递送载体及其制备方法和应用，属于药物递送载体技术领域。本发明提供的核酸递送载体基于LNP结构，保留关键脂质或类脂质不变，通过改变LNP的表面组成，可以有效减少LNP在肝脏中的积累，实现有效的mRNA原位传递和蛋白质表达；进而实现大幅改善LNP器官毒性、减轻mRNA药物副作用、提高mRNA药物耐受性的效果；通过促进载体的原位摄取量、增强内涵体逃逸两个方面实现原位靶向和核酸的高表达；通过对各组分和参数进行优化或添加活性脂质，均可以增强制备的核酸递送载体的原位表达水平和稳定性；在使用后，对施用部分进行超声，也可以促进核酸配送载体的原位表达水平。
Absstract of: CN120754274A
本申请涉及药物制剂的技术领域，具体涉及一种卡马西平的生产工艺及负载分散剂。本申请首先将β‑环糊精接枝于壳聚糖分子链上制得负载分散剂，然后在酸性条件下，负载分散剂中壳聚糖分子中的氨基被质子化后与羧甲基纤维素钠中的羧酸根负离子相互作用，形成纳米粒子，最后再负载卡马西平药物。通过上述生产工艺获得的纳米粒子含有疏水空腔，且具有较大的比表面积，因此载药量和包封率较高，累积释放率也较高，说明该纳米粒子载药后具有良好的溶出性能。另外，采用甲氧基聚乙二醇进一步改性后，在一定程度上可以提高载药纳米粒子的载药量和包封率，从而进一步提升其溶出性能。
Absstract of: CN120754063A
本发明公开了一种靶向免疫细胞的纳米载药系统。包括由聚乳酸‑羟基乙酸共聚物构成的核心纳米颗粒，用于包封治疗药物；包覆于核心表面的聚乙二醇功能层，延长血液循环时间；共价连接于聚乙二醇层的靶向配体，该配体为特异性识别免疫细胞表面受体的高亲和力配体，包括抗DEC205单链抗体片段、甘露糖或抗CD3抗体片段。创新点在于靶向配体对树突状细胞、巨噬细胞或T细胞表面特定受体的结合亲和力显著高于常规配体，且通过聚乳酸‑羟基乙酸共聚物‑聚乙二醇‑配体的协同结构实现高效胞内递送。技术效果包括体外对目标免疫细胞的摄取效率大幅提升，荷瘤小鼠肿瘤组织药物富集度较非靶向载体成倍提高，并显著增强抗原提呈和T细胞活化能力。
Absstract of: CN120757770A
本申请涉及一种聚乙二醇化顺铂化合物及其制备方法和应用，属于药物载体技术领域。本申请通过聚乙二醇与顺铂的共价偶联得到聚乙二醇化顺铂化合物。本申请提供了新型聚乙二醇化顺铂化合物及其制备方法、包含所述聚乙二醇化顺铂化合物以及含有该化合物的药物组合物及其制剂，尤其是含有该聚乙二醇化顺铂化合物的核酸药物组合物及其制剂，核酸药物组合物制剂能将核酸类药物递送至细胞内，提高核酸类药物的转运率，降低了毒性，从而提高核酸类药物的治疗效果。
Absstract of: CN120754060A
本申请公开了一种纳米载药系统及其制备方法和应用，纳米载药系统包括纳米颗粒、血小板膜、组织型纤溶酶原激活剂和凝血酶特异性适配体，血小板膜至少部分包覆纳米颗粒，组织型纤溶酶原激活剂和凝血酶特异性适配体连接于血小板膜。本申请的纳米载药系统，具有良好的靶向性、快速溶栓作用，且具有局部抗凝作用，有利于避免继发凝血和再栓塞风险。
Absstract of: CN120754131A
本发明属于技术领域，公开了一种用于皮肤疾病修复与抗衰老的干细胞外泌体组合物及其制备方法，产品采用MSC和ADSC外泌体的联合应用，在促进皮肤修复和抗衰老方面具有互补作用，MSC外泌体增强皮肤再生，而ADSC外泌体具有更好的抗炎和抗衰老作用，纳米胶囊载体不仅能提升外泌体的稳定性，还能优化其皮肤渗透性，延长外泌体的作用时间，通过加入皮肤屏障修复成分（如角鲨烯和神经酰胺），使得外泌体在修复皮肤的同时，还能够增强皮肤自我修复能力，改善皮肤屏障功能。
Absstract of: CN120757763A
本发明公开了一种碱性氨基酸修饰的3S‑PCL及其制备方法和用途，涉及生物医药技术领域。该碱性氨基酸修饰的3S‑PCL的结构式如下：；其中，R为碱性氨基酸；m、m1和m2均为正整数，且m、m1、m2≥1。本发明设计并合成了一种碱性氨基酸修饰的三臂聚己内酯（3S‑PCL）材料，其具有良好的生物相容性，可以替代阳离子脂质体用于脂质纳米粒核酸递送。该碱性氨基酸修饰的3S‑PCL材料制备方法简单快速，特别适合于工业化生产。以该碱性氨基酸修饰的3S‑PCL材料作为基因载体制备的脂质纳米粒可以实现对核酸药物的高效递送。
Absstract of: CN120754245A
本发明涉及肿瘤纳米医学技术领域，公开了一种改性普鲁士蓝纳米粒子及其制备方法和应用。所述改性普鲁士蓝纳米粒子为表面依次经鞣酸包覆和锰离子修饰的铪掺杂普鲁士蓝纳米颗粒，该改性普鲁士蓝纳米粒子，通过铪增强放疗增敏、普鲁士蓝介导光热治疗以及Mn2+激活STING免疫通路的三重机制，应用于制备骨肉瘤放疗药物时，能够显著提升抗肿瘤效果，体外试验验证其可通过ROS爆发、DNA损伤和凋亡三重机制根除肿瘤细胞，体内试验显示其可完全抑制原位骨肉瘤并消除肺转移，疗效显著优于单一疗法；通过鞣酸包覆赋予负电荷，实现静脉给药后高效肿瘤靶向，同时具备优异的生物相容性。
Absstract of: CN120754028A
本发明提供了一种负载镇痛药物的卵磷脂壳聚糖纳米粒凝胶及其制备方法和应用，属于医用生物材料技术领域。本发明通过将镇痛药物包载在卵磷脂壳聚糖纳米粒中，能够使镇痛药物缓慢释放，延长药物镇痛时间。本发明将包载镇痛药物的卵磷脂壳聚糖纳米粒分散在凝胶基质中，通过对凝胶基质的选择，使包载镇痛药物的卵磷脂壳聚糖纳米粒可以较快穿透皮肤角质层，使负载镇痛药物的卵磷脂壳聚糖纳米粒凝胶可以发挥速效透皮和缓释相药物相结合的作用，提高生物利用度，延长镇痛药物作用时间，发挥长时间镇痛的效果。
Absstract of: CN120754064A
本发明涉及纳米材料技术领域，具体涉及一种用于IBD治疗的单原子纳米酶递药系统及其制备方法和应用。本发明提供的单原子纳米酶递送系统，包括铁掺杂单原子纳米酶Fe‑SA、姜黄素Cur和透明质酸接枝多巴胺HAD；所述Fe‑SA与Cur通过配位作用形成Fe‑SA/Cur复合物，所述HAD包覆于所述Fe‑SA/Cur复合物表面。本发明中，所述铁掺杂单原子纳米酶Fe‑SA中Fe原子以Fe‑N4共掺杂形式分布于Fe‑SA的分级碳基基质中，具有高效的SOD和CAT纳米酶活性，能实现抗氧化自级联纳米酶反应，有效清除活性氧，改善病理环境。本发明利用铁掺杂单原子纳米酶和姜黄素构建配位复合物Fe‑SA/Cur，既增加了抗炎效果，又有效改善了姜黄素水溶性差的特点。本发明在配位复合物Fe‑SA/Cur外层负载HAD构建可口服的单原子抗氧化级联纳米酶系统，利用HAD显著的稳定性和负电荷实现了高耐酸性和靶向递送能力，有效实现了口服给药。体内外实验表明本发明提供的单原子纳米酶递送系统可有效清除肠道自由基，改善肠道环境，降低炎症因子表达，促进受损组织恢复，有效治疗结肠炎。本发明为炎症性肠病的生物医学研究和药物开发提供了新的思路和方法。
Absstract of: US2025312287A1
The present invention relates to compositions for in vitro and in vivo delivery of nucleic acids, in particular messenger RNAs (mRNAs), into a target cell and their applications. The present invention is directed to a composition comprising (A) at least one nucleic acid and (B) at least one lipid nanoparticle (LNP) comprising (i) at least one ionizable lipid; (ii) at least one phospholipid; (iii) at least one sterol, especially neutral sterol; (iv) at least one poly(ethyleneglycol)-lipid (PEG-lipid); and (v) an imidazolium-based cationic lipid of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9, Y and A− are as defined in the description. The present invention also relates to a method for in vitro or in vivo transfection of live cells and uses of said composition.
Absstract of: WO2025208337A1
Disclosed is a biomimetic nano-delivery system, comprising an inner core formed from a black phosphorus nanosheet and a drug, and a shell formed from an M1-type macrophage membrane. The biomimetic nano-delivery system has an anti-tumor effect, has a good photothermal effect under the irradiation of a near-infrared laser, and can actively recognize tumor cells and release the drug precisely and efficiently.
Absstract of: US2025312289A1
This application relates in part to nanoparticles comprising a tobamovirus and nanoparticles comprising a tobamovirus and beta-cyclodextrin (β-CD or BCD). This application also relates in part to nanoparticles comprising tobamovirus and one or more active ingredients (AIs) that are non-covalently conjugated to the tobamovirus. The application also provides methods of making and methods of using such nanoparticles as well as compositions comprising the disclosed nanoparticles.
Absstract of: US2025312288A1
The present disclosure relates generally to lipids, lipid nanoparticle formulations, and methods of using the same for delivering nucleic acids, such as mRNA.
Absstract of: US2025313525A1
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
Absstract of: US2025313531A1
Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
Absstract of: US2025313835A1
The present disclosure includes cationic carrier units comprising (i) a water-soluble polymer, (ii) a positively charged carrier, (iii) a hydrophobic moiety, and (iv) a crosslinking moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.
Absstract of: US2025313675A1
Described herein are flash nanoprecipitation methods capable of encapsulating hydrophobic molecules, hydrophilic molecules, bioactive protein therapeutics, or other target molecules in amphiphilic copolymer nanocarriers.
Absstract of: US2025312498A1
Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.
Nº publicación: US2025312485A1 09/10/2025
Applicant:
THE TRUSTEES OF THE UNIV OF PENNSYLVANIA [US]
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Absstract of: US2025312485A1
Compositions and methods for effecting base editing to correct mutations in the phenylalanine hydroxylase gene, thereby curing phenylketonuria, are disclosed.
BOPI
Electronic site
